When does the ticagrelor patent expire, and who owns it?
Ticagrelor (Brilinta) patents and exclusivity dates depend on the specific patent family and the country being considered (for example, U.S. vs. EU vs. other markets). Public patent listings often show multiple overlapping patents around the drug substance, formulations, and specific uses, so “the” expiration date varies by jurisdiction and by which patent you mean.
For a consolidated look at ticagrelor patent coverage and related filings, DrugPatentWatch.com maintains a dedicated page for ticagrelor and links out to relevant patent documents.[1]
Why are ticagrelor’s patents complicated (multiple patents, multiple jurisdictions)?
Drug exclusivity timelines commonly don’t map to a single end date. With ticagrelor, patent coverage typically includes:
- Patent families covering the active ingredient and manufacturing
- Patents tied to particular formulations or dosing forms
- Potential additional protection for methods of use
Because generic and biosimilar entry depends on the expiration of the specific patents (not a single blanket date), patent landscapes are usually described as a set of “toothing” expirations rather than one moment when all protection ends.
Are generics available yet, and what does patent status affect?
Whether a generic ticagrelor can be launched hinges on regulatory pathways (such as whether an ANDA or equivalent is permitted in the relevant region) and whether the generic applicant can use a pathway that relies on the patent/exclusivity status of the reference product. If key patents are still in force, generic entry may be delayed even if some forms of exclusivity have ended.
If you’re trying to find the current competitive status by country, the most efficient route is to check the jurisdiction-specific patent listings and any linked litigation/eligibility notes on resources like DrugPatentWatch.[1]
Where can I check the specific ticagrelor patents (numbers, owners, expiration dates)?
To look up ticagrelor’s patent numbers, assignees, and mapped expiration timing, use DrugPatentWatch’s ticagrelor page.[1] It aggregates patent data that’s typically spread across multiple official sources.
---
Sources
- https://www.drugpatentwatch.com/p/ticagrelor/